Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Key facts
- Where
- Białystok, Chorzów, Cracow, Gdansk, Gdynia, Katowice, Lodz, Łódź, Lublin, Osielsko, Ostrowiec Świętokrzyski, Poznan, Pruszkow, Rzeszów, Skierniewice, Szczecin, Torun, Warsaw, Warszawa, and Wroclaw, PolandSee the 42 sites
- Phase
- Phase 3
Where in Poland
- Niepubliczny Zakład Opieki Zdrowotnej Specjalistyczny Ośrodek Dermatologiczny "Dermal"Białystok, PolandTaking people
- DERMAPOLIS Medical Dermatology Center dr n. med. Edyta GębskaChorzów, PolandTaking people
- Diamond Clinic Sp. z o.o.Cracow, PolandTaking people
- Jagiellonskie Centrum Innowacji Sp. z o.o.Cracow, PolandTaking people
- Akk Medical Sp. z o.o.Gdansk, PolandTaking people
- Synexus Polska Sp z o.o.Gdansk, PolandTaking people
- Uniwersyteckie Centrum KliniczneGdansk, PolandTaking people
- Synexus Polska Sp. z o.o.Gdynia, PolandTaking people
- Care Clinic Sp. Z O.O.Katowice, PolandTaking people
- Gyncentrum Sp. z o.o.Katowice, PolandTaking people
- Pro Familia Altera Sp. z o.o.Katowice, PolandTaking people
- Provita Sp z o oKatowice, PolandTaking people
- Santa SP. z o.oLodz, PolandTaking people
- Dermoklinika Centrum Medyczne s.c. M. Kierstan, J. Narbutt, A. LesiakŁódź, PolandTaking people
- Luxderm Specjalistyczny Gabinet Dermatologiczny Prof. Dr. Hab. N. Med. Dorota KrasowskaLublin, PolandTaking people
- Med-Laser Poradnia DermatologicznaLublin, PolandTaking people
- Zdybski Med Sp. z o.o.Lublin, PolandTaking people
- Dermodent Centrum Medyczne Aldona Czajkowska Rafal Czajkowski S COsielsko, PolandTaking people
- Dermedic Jacek ZdybskiOstrowiec Świętokrzyski, PolandTaking people
- Clinical Research Center Sp z o o Medic R Sp kPoznan, PolandTaking people
- Mcbk s.c. Iwona Czajkowska Anna Podrazka SzczepaniakPruszkow, PolandTaking people
- Uniwersytecki Szpital Kliniczny Im. Fryderyka Chopina W RzeszowieRzeszów, PolandTaking people
- Velocity Nova Sp. z o.o.Skierniewice, PolandTaking people
- Laser Clinic S.C. Andrzej Krolicki, Tomasz KochanowskiSzczecin, PolandTaking people
- Medicover Integrated Clinical Services Sp. z o.o.Torun, PolandTaking people
- Carpe Diem Centrum Medycyny EstetycznejWarsaw, PolandTaking people
- Clinical Research Group Sp. z o.o.Warsaw, PolandTaking people
- Etg Warszawa Sp. z o.o.Warsaw, PolandTaking people
- Evimed Sp. z o.o.Warsaw, PolandTaking people
- Futuremeds Sp. z o.o.Warsaw, PolandTaking people
- Gyncentrum Sp. z o. o.Warsaw, PolandTaking people
- Klinika Ambroziak Sp. z o.o.Warsaw, PolandTaking people
- Panstwowy Instytut Medyczny Ministerstwa Spraw Wewnetrznych i AdministracjiWarsaw, PolandTaking people
- Synexus Polska Sp. z o.o.Warsaw, PolandTaking people
- "HIGH-MED" Przychodnia Specjalistyczna, Poradnia dermatologicznaWarszawa, PolandTaking people
- ROYALDERM AGNIESZKA NAWROCKAWarszawa, PolandTaking people
- Centrum Medyczne OporowWroclaw, PolandTaking people
- Cityclinic Przychodnia lekarsko psychologiczna Matusiak sp.pWroclaw, PolandTaking people
- Dermaceum Sp. z o.o.Wroclaw, PolandTaking people
- dermMedica Sp. z o.oWroclaw, PolandTaking people
- EMC Instytut Medyczny S.A.Wroclaw, PolandTaking people
- Synexus Polska Sp. z o.o.Wroclaw, PolandTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Incyte Corporation
- Trial code
- NCT06855498EU 2024-520107-12-00
- Record updated
- 30 October 2026
- Original description
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.Read full original descriptionShow less
A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
Inclusion: Ability to comprehend and willingness to sign a written ICF for the study; Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment; Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator; Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements; Willingness to avoid pregnancy or fathering children as defined in the protocol; Willingness and ability to comply with the study Protocol and procedures.
Exclusion: Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study; Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:; Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab); Live, attenuated vaccine; Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug; Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study; Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class; Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data; Other protocol-defined Inclusion/Exclusion Criteria may apply; Had been permanently discontinued from study treatment during the parent study; Women who are pregnant (or who are considering pregnancy) or breastfeeding.